Drug Trial Radar · NCT04415918
Bezlotoxumab Efficacy and Tolerability in Cancer Patient
Last checked: Nov 20, 2026Latest source record: Jun 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
132
Planned (sponsor's estimate)
Start
Jul 1, 2020
Primary completion
Jul 1, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Cooper Norcross HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence.
Conditions
- Clostridium Difficile Infection Recurrence
Interventions
Bezlotoxumab InjectionDrug
A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with recurrent CDIs within 12 weeks of initial cure compared with historical group of patients selected with same inclusion/exclusion criteria (same center within 3 years of the start date of the study).Time frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.